Archive: May 2018

Why biotech startups need “smart capital”?

In many people's eyes, biotech companies are money blackholes. A typical startup spends its first 5 or even 10 years of life consuming huge sums of cash, without churning out any revenue, let alone profit. This doesn't sound like an attractive proposition to either entrepreneurs or investors. After all, everyone wants a bit more transparency and a little certainty along the journey. Is this possible?

How bereaved parents became ‘accidental world leaders’ in 3D printing

Naveed and Samiya Parvez watched their son, who had cerebral palsy, suffer distressing measuring methods to get the splints and braces he needed. Now, they’ve revolutionised the process

The biotech conundrum – is patient capital the solution?

Starting a biotech company is a monumental task. Entrepreneurs need to be prepared to commit for the long term, and spend tens or hundreds of millions of dollars before reaching the first customer. It is a dark and winding tunnel fraught with traps; at any point the doors can slam shut because of a tiny misstep, or from forces outside the founders’ control. The company can become worthless overnight if a key product fails to demonstrate sufficient efficacy in a clinical trial, or if the company can’t raise further capital to continue. 10 years of sweat and toil can go to waste in an instant.